Li J, Tanhehco EJ, Russell B. Actin dynamics is rapidly regulated by the PTEN and PIP2 signaling pathways leading to myocyte hypertrophy.
THE ADDITION OF SARCOMERIC units to cardiomyocytes requires filaments to be added for cardiac hypertrophy. Live imaging of actin in striated muscle has revealed that actin subunits in the thin filaments are dynamically exchanged (32) . One of the regulators for actin dynamics is the actin capping protein Z (CapZ), and malfunction of CapZ resulted in disorganization of myofibril structures or disease (29) . Both enhancers and stabilizers of actin dynamics are important for myocyte hypertrophy. However, the mechanisms for actin filament addition are not yet well understood.
PIP 2 is a lipid messenger in its own right, instead of simply being a precursor of messengers. Direct interaction of PIP 2 with the actin accessory proteins profilin and gelsolin promoted or inhibited assembly of F-actin filaments (10, 12) . Recently, our group showed that PIP 2 binding to CapZ␤1 altered sarcomeric actin dynamics in cultured cardiomyocytes (8, 14) . Many PIP 2 effector proteins function in other organelles, for example in focal adhesion formation, vesicle trafficking via integrin, or E-cadherin, and at sites of mRNA processing in the nucleus (18, 24, 19, 36) . PIP 2 was localized to the Z-disc, which suggested its role in sarcomeric reorganization (14) . Furthermore, PIP 2 is implicated in ANG II-induced cardiac hypertrophy in an animal model (40) .
The phosphatase and tensin homolog (PTEN) has numerous roles but was originally established as one of the most frequently mutated tumor suppressor genes in human cancer. PTEN is a 3=-lipid phosphatase, which comprises an NH 2 -terminal phosphatase domain, an NH 2 -terminal PIP 2 -binding polybasic tail, a C2 domain, and a COOH-terminal tail region that contains multiple phosphorylation sites (13, 23) . Much is known about PTEN chemistry and its action for the control of cell number. However, less is understood about cell size regulation even though PTEN is widely expressed in cardiomyocytes (4, 34) . The mechanisms involving PTEN in cardiac hypertrophy are controversial. The inactivation of PTEN increased cell size and growth by amplifying PI3K signaling, whereas overexpression of PTEN inhibited PI3K signaling, resulting in decreased cell size (11) . However, a recent study identified that the loss of PTEN could prevent the development of maladaptive ventricular remodeling in response to pressure overload but not in response to ANG II, suggesting that additional complex regulatory pathways may exist (27) .
The main physiological substrate of PTEN is membranebound PIP 3 , and PTEN is activated when recruited to the plasma membrane (5) . PTEN converted the lipid second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ) to PIP 2 (22) , as a negative regulator of phosphoinositide 3-kinase (PI3K) signaling. Thus the balance between PTEN and PI3K controls the basal levels of PIP 3 in the plasma membrane, which in turn regulates cell survival and proliferation. Therefore, the activity and intracellular distribution of PTEN after treatment with the ANG II stimulus were measured in this study to test the hypothesis that PTEN plays a key role via PIP 2 in regulating actin dynamics in cardiomyocytes. Our findings show that stimulation by ANG II increased the activity of PTEN, the level of PIP 2 , and dynamics of actin filament, resulting in increased cell size. Therefore, PTEN and PIP 2 signaling may play an important role in myocyte hypertrophy by the regulation of actin filament dynamics, which is induced by ANG II stimulation.
MATERIALS AND METHODS
Ethical approval. All experiments were conducted following National Institutes of Health guidelines. All experiments were approved by the University Committee on the Use and Care of Animals at the University of Illinois at Chicago and the Biologic Resources Laboratory. All euthanasia was performed following the recommendations of the University Committee on the Use and Care of Animals and the Biologic Resources Laboratory and the Committee for the Humane Use of Animals.
Animals. Eight 8-wk-old C57B6/J mice were randomly divided into two groups of four animals. ANG II (Sigma-Aldrich) was administered with osmotic mini-pumps (Alzet model 1002, 1 g·g Ϫ1 ·day Ϫ1 ) for 2 wk. In the control group, mice received vehicle (saline solution) for 2 wk. The dosage of ANG II was chosen from previous studies (20) , which induced left ventricle hypertrophy in mice as confirmed by heart and weight measurements.
NRVM culture. Hearts were removed and cells isolated from 1-to 2-day-old Sprague-Dawley rats with collagenase type II (Worthington, Lakewood, NJ) as previously described (3). NRVMs were resuspended, filtered through a metal sieve to remove large material, and plated at high density (1, Subcellular fractionation and localization of PTEN. For subcellular fractionation of myocytes, the Calbiochem ProteoExtract Subcellular Proteome Extraction Kit was used (Catalog No. 539790; EMD Millipore, Billerica, MA), following a previously described detergentbased protocol (2) . Cellular proteins were sequentially extracted into four compartments: cytosolic, membrane/organelles, nuclei, and cytoskeleton. In this study, only cytosol and membrane were needed. Digitonin-EDTA is used to remove the cytosol. Triton-EDTA is used to remove the membrane-organelle fraction. Cells were briefly washed three times in PBS between each extraction fraction to prevent cross-contamination. After each fraction, cells were observed by microscopy to ensure that they were still attached to the dish. Cell integrity is maintained throughout the fractionation process. The accuracy of the fractionation method was verified with antibodies to well-documented subcellular distribution markers [heat shock protein (Hsp)70 for cytostol, ␤-integrin for membrane; anti-Hsp70 from Catalog No. sc-24, Santa Cruz Biotechnology, Dallas, TX; anti-␤-integrin from Catalog No. MAB1900, EMD Millipore]. Experiments were repeated at least three times.
PTEN lipid phosphatase activity. For the measurement of in vitro PTEN lipid phosphatase activity, the ELISA phosphatase assay kit (Echelon Biosciences) was used according to the manufacturer's instructions. Briefly, 500 g of cell lysate was subjected to PTEN immunoprecipitation by the addition of 4 l anti-PTEN mAb (Catalog No. 04-035; EMD Millipore), and the immunocomplex formed was captured by incubation with 20 l protein A/G beads with gentle rotation at 4°C overnight. The beads were then washed twice in lysis buffer and once in enzyme reaction buffer (ERB) containing (in mM) 50 Tris·HCl (pH 8.0), 50 NaCl, 10 DTT, and 10 MgCl 2 and distributed in triplicates of 30 l in a 96-well flat-bottom plate (Echelon). The reaction was initiated by adding 30 l of ERB containing the substrate dioctanoyl phosphatidylinositol 3,4,5-trisphosphate (PIP 3-DiC8) (P-3908; Echelon) to 8 M final concentration. After 1 h at 37°C, the reaction was stopped by 60 l ERB. An additional detector and stop solution were added for 30 min, and then the absorbance was read at 450 nm after 30 min. A PIP 3-only blank was used in parallel to correct for potential nonspecific phosphate release. The remaining beads were used for SDS-PAGE, Western blotting, and densitometric quantification to confirm that equivalent amounts of PTEN were immunoprecipitated from all samples. A standard curve was made by using the phosphate solution provided with the kit. The PTEN activity was expressed as of control group.
Fluorescence recovery after photobleaching for actin dynamics. Recently, several microscopic techniques, such as fluorescence recovery after photobleaching (FRAP) (31) have yielded qualitative and quantitative information about the processes that regulate actin polymerization in living myocytes. The methods and analysis for FRAP of actin-GFP were described by our laboratory (17) . In the present study, five myocytes were analyzed per culture and at least three separate cultures were studied per experimental condition.
Statistics. Data are presented as means Ϯ SE. Statistical significance was determined by one-way ANOVA. Significance was taken as P Ͻ 0.05.
RESULTS

Increased actin dynamics and cardiomyocyte hypertrophy induced by ang II are dependent on the PIP 2 pathway.
The FRAP experiments revealed differences after ANG II treatment (Fig. 1) . After 1 h of ANG II treatment, the actin-GFP had a faster dynamic protein exchange in ANG II-treated myocytes than the vehicle group (12.30 Ϯ 1.62 vs. 7.70 Ϯ 1.23, ϫ 10 Ϫ4 s Ϫ1 , P Ͻ 0.05; Fig. 1 , A and B and Table 1 ). In NRVMs stimulated by ANG II and the PIP 2 scavenger neomycin, the increased dynamics of actin-GFP were markedly reduced compared with ANG II treatment alone (7.28 Ϯ 1.19 vs. 12.30 Ϯ 1.62, ϫ10 Ϫ4 s
Ϫ1
, P Ͻ 0.05; Table 1 ), demonstrating that dynamic exchange of actin-GFP is dependent on the PIP 2 pathway after ANG II treatment.
To determine whether PIP 2 is involved in cardiac hypertrophy, NRVMs were treated with neomycin and ANG II for 48 h. Neomycin alone had no effects on myocardial size or phenotype, indicating that the effect of neomycin was not secondary to a toxic cellular effect. ANG II induced approximately a 40% increase in myocyte size, which was inhibited by neomycin treatment (27%; Fig. 1, C and D) . These results suggest that neomycin attenuates ANG II induced cardiac hypertrophy and PIP 2 plays an important role in it.
PIP 2 increases in ang II-induced cardiac hypertrophy. ANG II treatment in the mouse was used to test the hypothesis that PIP 2 has a role in cardiac hypertrophy in vivo. The heart weight-to-body weight ratio (HW/BW) showed a significant increase in the ANG II-induced cardiac hypertrophy (Fig. 2C and Table 2 ). The PIP 2 level increased significantly (P Ͻ 0.05) in ANG II-induced hypertrophic heart (Fig. 2, A and B) . The PIP 2 level increased in ANG II-stimulated NRVMs (Fig. 2, D and E), indicating that PIP 2 may be involved in the ANG II-stimulated NRVM hypertrophic response.
Increased PIP 2 production by ANG II is dependent on the PTEN pathway. The PIP 2 level was significantly increased in NRVMs after a 1-h treatment of ANG II, and PIP 3 level was markedly decreased (Fig. 3, A and B) . By prevention of PTEN activity through pharmacological inhibition with bpV (1 M), ANG II-induced PIP 2 was markedly reduced. In contrast, the reduced PIP 3 in ANG II group was strikingly increased with inhibition of activity of PTEN by bpV (Fig. 3, A and B) . To confirm the PTEN inhibition study, a specific PTEN inhibitor SF1670 originally used in neutrophils (15) and was confirmed here in cardiomyocytes. ANG II increased PIP 2 , which was significantly reduced by SF1670 treatment while also dramatically increasing PIP 3 (Fig. 3, A and B) . Thus, these data strongly suggest the role for PTEN in regulating ANG IIinduced PIP 2 production in cardiac myocytes.
Inhibition of PTEN activity attenuates ang II-induced increased actin dynamics. To determine whether the effects of PIP 2 on actin dynamics could be attenuated, NRVMs were pretreated with bpV or SF1670 for 30 min and then subjected to ANG II for 1 h. The marked increase in actin-GFP dynamics induced by ANG II was significantly inhibited by bpV (7.45 Ϯ 1.12 vs. 12.30 Ϯ 1.62, ϫ10 Ϫ4 s Ϫ1 , P Ͻ 0.05) or by SF1670 Table 1 ). bpV or SF1670 alone had no effects on actin dynamics, indicating that the effect of bpV or SF1670 was not secondary to a toxic cellular effect. These results suggest that the activity of PTEN plays an important role in ANG IIinduced cardiac hypertrophy.
ANG II stimuli activate PTEN. PTEN activation might be important since the PTEN inhibition blunted PIP 2 and PIP 3 levels and actin dynamics by ANG II. Therefore, NRVMs were treated with ANG II and PTEN inhibitors (bpV or SF1670), and PTEN activity was measured by ELISA PTEN activity kit (Echelon Biosciences). Assessment of PTEN activity showed that ANG II stimulation in NRVMs resulted in significantly increased lipid phosphatase activity of PTEN compared with the control group, and it was blunted by the inhibitors of PTEN bpV or SF1670 (Fig. 4) . This suggests that activity of PTEN may be involved in the PIP 2 production by ANG II, since PTEN converts PIP 3 to PIP 2 . 2 and PIP 3 levels and the translocation of PTEN by ang II. The relative time courses of levels of PIP 2 and PIP 3 with ANG II are shown in Fig. 5 . ANG II induced an increase of PIP 2 , which was detected at 30 min and sustained at 60 min. In contrast, PIP 3 was decreased by ANG II, beginning at 30 min and staying low at 60 min.
Time course of PIP
The PTEN level in ANG II-induced cardiomyocytes was examined. The protein level of PTEN in ANG II-treated NRVMs was not significantly changed at different time points up to 60 min (Fig. 6, A and D) . The plasma membrane fraction of PTEN was significantly increased by 10 min (Fig. 6, B and E) , although the total amount of PTEN and cytosolic fraction was not altered (Fig. 6, C and F) . Because PIP 2 production was increased at 30 min, which is later than the translocation of PTEN to plasma membrane by 10 min, these results suggest that the translocation of PTEN precedes the production of PIP 2 . Fig. 2 . Increased phosphatidylinositol 4,5-bisphosphate (PIP2) production in mouse heart and in cultured NRVMs by ANG II treatment. A and B: dot blot analysis of PIP2 was significantly increased in the heart after 2 wk of ANG II delivery by mini-pump. GAPDH was used to normalize the dot blot density. Means Ϯ SE; *P Ͻ 0.05, n ϭ 3. The increased heart weight (HW)-to-body weight (BW) ratio (C) in ANG II-treated mice showed significant cardiac hypertrophy. *P Ͻ 0.05, n ϭ 3. D and E: after 1 h stimulation by ANG II, PIP2 production dramatically increased in the ANG II-treated group. Means Ϯ SE. *P Ͻ 0.05, n ϭ 3. C, control. 
DISCUSSION
The present study demonstrates that actin dynamics and cell size were increased in NRVMs by stimulation with ANG II, which were tightly correlated to changes in the PTEN and PIP 2 pathways. Furthermore, the PIP 2 and PIP 3 production by ANG II treatment was dependent on the PTEN pathway. The model proposed is that PTEN redistributes to the plasma membrane where it converts PIP 3 to PIP 2 (Fig. 7) . Our results suggest that a possible mechanism for thin filament assembly partly relies on this increased level of PIP 2 .
The regulation of organization of the actin cytoskeleton upon G protein-coupled receptors (GPCRs) signaling has rarely been addressed. The angiotensin receptor (ATR) is one of the GPCRs, but a mechanism for the direct regulation of sarcomeric actin dynamics by the ATR has not yet been reported. However, there are some complicated clues that suggest that the ATR might regulate actin assembly through inhibiting PI3K pathways via ␤-arrestin (6, 28, 37) Some other GPCRs have been shown to regulate nonsarcomeric actin dynamics through different mechanisms. For example, serotonin receptors affected F-actin reorganization through cAMP signaling (7), endothelin receptors activated and induced association of paxillin with a cytoskeleton-enriched membrane fraction in vascular tissue (26) , and ACh receptors played a role in cytoskeletal remodeling during AChinduced contraction of smooth muscle through tyrosine phosphorylation of paxillin (35) . Therefore, a mechanism involving the angiotensin receptor regulation of sarcomeric actin dynamics in cardiomyocytes is a possibility. Hypertrophy, resulting from chronic demands, requires addition of new sarcomeres. In the present study, we focused on the initial changes to sarcomeric actin dynamics after 1 h of ANG II treatment. Cell sizes in NRVMs and the PIP 2 level in ANG II-induced hypertrophic mouse heart were shown after 2 days and 1 wk, respectively. Thus the acute parameters of actin dynamics precede actual cardiac hypertrophy by an interval in which many additional steps could occur, rather than being a direct linkage.
PIP 2 , has a direct role in regulating actin assembly by interaction with partnering proteins in many cells. In platelets, the half-life for a capped filament was 28 min, whereas the half-life to remain uncapped was only 0.2 s. Interestingly, the addition of PIP 2 in these platelets reduced the half-life of the capped filament to 46 s, suggesting PIP 2 regulation of actin filament capping dynamics (33) . Our previous study clearly showed that PIP 2 localized to the Z-disc in cardiomyocytes and regulated actin filament dynamics (14) . In the present study, the increased actin dynamics by ANG II was in a PIP 2 -dependent manner (Fig. 1) , suggesting PIP 2 may play a critical role in increased actin assembly by ANG II induction.
The next question is how PIP 2 is produced by ANG II. Some signaling pathways, such as PKC and PI4K, were involved in producing PIP 2 in myocytes isolated from adult mice treated with ANG II (40) . In addition, the PIP 2 level could be converted at plasma membrane to PIP 3 by PTEN, which is one of the regulators of PIP 2 located there. In our results, the PTEN was activated by ANG II in NRVMs (Fig. 4) , and PIP 2 and PIP 3 levels induced by ANG II were conversely changed by PTEN inhibition, suggesting that PTEN plays a role in PIP 2 production by ANG II. There are two main explanations of how PTEN binds to the plasma membrane. The binding of PTEN to PIP 2 might be critical for membrane localization (9) . In contrast, PTEN might interact with the nonspecific electrostatic charges at the plasma membrane arising from lipids, such as phosphatidylserine (25) . In our time course results, PTEN significantly increased at plasma membrane after only 10 min of ANG II stimulation (Fig. 6, B and E) , whereas increased PIP 2 /decreased PIP 3 did not change significantly until 30 min (Fig. 5) . This time sequence suggests that PTEN interacted with the plasma membrane first and then converted PIP 3 to PIP 2 at plasma membrane.
Since the majority of cellular PTEN is found in the cytosol (30), how is PTEN able to execute different cellular functions that require its membranous lipid phosphatase activity? The lipid phosphatase activity of PTEN is at the plasma membrane. The plasma membrane PTEN increased in a time-dependent manner with ANG II treatment (Fig. 6, B and E) . A decrease of cytosolic PTEN was expected but not found (Fig. 6, C and F) perhaps because most of the PTEN remains in this compartment. The level of PTEN in unstimulated myocytes was over 50-fold higher in the cytosol than in the membrane detected by Western blotting (data not shown).
The phosphatase activity of PTEN was significantly increased in ANG II-treated cardiomyocytes, whereas it was blunted by PTEN inhibitors bpV or SF1670 (Fig. 4) . The subcellular localization of PTEN and its enzymatic activity are regulated by its various posttranslational modifications. PTEN contains multiple domains, including an NH 2 -terminal phosphatase domain, a central C2 domain, and a COOH terminal tail. The phosphorylation sites mapped on PTEN could be serine and threonine residues (39), Ser370 and Ser385 (38) and Ser362 and Thr366 (1) in its COOH-terminal tail. Furthermore, PTEN was phosphorylated by RhoA-associated kinase at Ser229, Thr232, Thr319, and Thr321 in the C2 domain (16) . In contrast, Thr366 phosphorylation promoted PTEN degradation (21) . In this study, the focus was on the membrane translocation of PTEN that may contribute to its lipid phosphatase activity, since there are so many phosphorylation sites in inactive PTEN in cytosol. Our results were consistent with changes seen in cultured cardiomyocytes whereby ANG IIinduced increased actin dynamics was blocked by the PTEN inhibitor bpV or SF1670 (Fig. 3C ).
In conclusion, PIP 2 plays a major role in regulating actin cytoskeleton dynamics. Furthermore, our results provide a crucial link between PTEN and the cellular responses to ANG II in which the translocation of PTEN was associated. We speculate that similar mechanisms may be responsible for ventricular remodeling and progression to heart failure.
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